A citation-based method for searching scientific literature

Reprogramming Innate Immune Signaling in Cardiometabolic Disease.
Yaxing Zhang, Xiao-Jing Zhang, Pi-Xiao Wang, Peng Zhang, Hongliang Li. Hypertension 2017
Times Cited: 19






Login to export Results
Don't have an account? Register here

List of co-cited articles
406 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.
Yan-Xiao Ji, Peng Zhang, Xiao-Jing Zhang, Yi-Chao Zhao, Ke-Qiong Deng, Xi Jiang, Pi-Xiao Wang, Zan Huang, Hongliang Li. Nat Commun 2016
117
12
63

Reprogramming Interferon Regulatory Factor Signaling in Cardiometabolic Diseases.
Yaxing Zhang, Hongliang Li. Physiology (Bethesda) 2017
22
11
57

Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling.
Pi-Xiao Wang, Xiao-Jing Zhang, Pengcheng Luo, Xi Jiang, Peng Zhang, Junhong Guo, Guang-Nian Zhao, Xueyong Zhu, Yan Zhang, Sijun Yang,[...]. Nat Commun 2016
94
11
57

Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.
Guang-Nian Zhao, Peng Zhang, Jun Gong, Xiao-Jing Zhang, Pi-Xiao Wang, Miao Yin, Zhou Jiang, Li-Jun Shen, Yan-Xiao Ji, Jingjing Tong,[...]. Nat Med 2017
93
11
57

Interferon regulatory factor 3 constrains IKKβ/NF-κB signaling to alleviate hepatic steatosis and insulin resistance.
Xin-An Wang, Ran Zhang, Zhi-Gang She, Xiao-Fei Zhang, Ding-Sheng Jiang, Tao Wang, Lu Gao, Wei Deng, Shu-Min Zhang, Li-Hua Zhu,[...]. Hepatology 2014
108
10
52

The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.
Feng-Juan Yan, Xiao-Jing Zhang, Wen-Xin Wang, Yan-Xiao Ji, Pi-Xiao Wang, Yang Yang, Jun Gong, Li-Jun Shen, Xue-Yong Zhu, Zan Huang,[...]. Hepatology 2017
52
10
52

Interferon regulatory factor signalings in cardiometabolic diseases.
Xiao-Jing Zhang, Peng Zhang, Hongliang Li. Hypertension 2015
40
9
47

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.
Mei Xiang, Pi-Xiao Wang, Ai-Bing Wang, Xiao-Jing Zhang, Yaxing Zhang, Peng Zhang, Fang-Hua Mei, Man-Hua Chen, Hongliang Li. J Hepatol 2016
96
9
47

Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.
Ling Gao, Pi-Xiao Wang, Yaxing Zhang, Chang-Jiang Yu, Yanxiao Ji, Xiaozhan Wang, Peng Zhang, Xi Jiang, Hong Jin, Zan Huang,[...]. J Hepatol 2016
36
8
42

Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury.
Pi-Xiao Wang, Ran Zhang, Ling Huang, Li-Hua Zhu, Ding-Sheng Jiang, Hou-Zao Chen, Yan Zhang, Song Tian, Xiao-Fei Zhang, Xiao-Dong Zhang,[...]. J Hepatol 2015
57
8
42

Hepatic Oncostatin M Receptor β Regulates Obesity-Induced Steatosis and Insulin Resistance.
Pengcheng Luo, Pi-Xiao Wang, Zuo-Zhi Li, Xiao-Jing Zhang, Xi Jiang, Jun Gong, Juan-Juan Qin, Junhong Guo, Xueyong Zhu, Sijun Yang,[...]. Am J Pathol 2016
24
8
42

The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.
Peng Zhang, Pi-Xiao Wang, Ling-Ping Zhao, Xin Zhang, Yan-Xiao Ji, Xiao-Jing Zhang, Chun Fang, Yue-Xin Lu, Xia Yang, Mao-Mao Gao,[...]. Nat Med 2018
118
8
42

The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.
Yan-Xiao Ji, Zan Huang, Xia Yang, Xiaozhan Wang, Ling-Ping Zhao, Pi-Xiao Wang, Xiao-Jing Zhang, Michele Alves-Bezerra, Lin Cai, Peng Zhang,[...]. Nat Med 2018
79
8
42

Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.
Jingjing Cai, Meng Xu, Xiaojing Zhang, Hongliang Li. Annu Rev Pathol 2019
44
8
42

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.
Pi-Xiao Wang, Yan-Xiao Ji, Xiao-Jing Zhang, Ling-Ping Zhao, Zhen-Zhen Yan, Peng Zhang, Li-Jun Shen, Xia Yang, Jing Fang, Song Tian,[...]. Nat Med 2017
142
7
36

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
3032
7
36

The innate immune signaling in cancer and cardiometabolic diseases: Friends or foes?
Weijun Wang, Yaxing Zhang, Ling Yang, Hongliang Li. Cancer Lett 2017
15
7
46

Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Trends Endocrinol Metab 2018
44
7
36

Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases.
Meng Xu, Peter P Liu, Hongliang Li. Physiol Rev 2019
42
7
36

Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury.
Junfei Hu, Xue-Hai Zhu, Xiao-Jing Zhang, Pi-Xiao Wang, Ran Zhang, Peng Zhang, Guang-Nian Zhao, Lu Gao, Xiao-Fei Zhang, Song Tian,[...]. J Hepatol 2016
70
6
31

Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice.
Xin-An Wang, Ran Zhang, Dingsheng Jiang, Wei Deng, Shumin Zhang, Shan Deng, Jinfeng Zhong, Tao Wang, Li-Hua Zhu, Li Yang,[...]. Hepatology 2013
64
6
31

Progress and challenges in the prevention and control of nonalcoholic fatty liver disease.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Med Res Rev 2019
69
6
31

DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.
Lanfeng Xie, Pi-Xiao Wang, Peng Zhang, Xiao-Jing Zhang, Guang-Nian Zhao, Aibing Wang, Junhong Guo, Xueyong Zhu, Qin Zhang, Hongliang Li. J Hepatol 2016
47
6
31

Liver capsule: IRFs in hepatocytes: Pathophysiology.
Pi-Xiao Wang, Xiao-Jing Zhang, Hongliang Li. Hepatology 2016
10
6
60

CARD3 deficiency exacerbates diet-induced obesity, hepatosteatosis, and insulin resistance in male mice.
Xin-An Wang, Shan Deng, Dingsheng Jiang, Ran Zhang, Shumin Zhang, Jinfeng Zhong, Li Yang, Tao Wang, Shufen Hong, Sen Guo,[...]. Endocrinology 2013
20
6
31

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases.
Yao Yu, Jingjing Cai, Zhigang She, Hongliang Li. Adv Sci (Weinh) 2018
77
6
31

The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Hepatology 2019
91
6
31

Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.
Ze Chen, Yao Yu, Jingjing Cai, Hongliang Li. Trends Endocrinol Metab 2019
57
6
31

Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance.
Xin-An Wang, Ran Zhang, Shumin Zhang, Shan Deng, Dingsheng Jiang, Jinfeng Zhong, Li Yang, Tao Wang, Shufen Hong, Sen Guo,[...]. Am J Physiol Endocrinol Metab 2013
69
5
26

Interferon regulatory factor 9 is critical for neointima formation following vascular injury.
Shu-Min Zhang, Li-Hua Zhu, Hou-Zao Chen, Ran Zhang, Peng Zhang, Ding-Sheng Jiang, Lu Gao, Song Tian, Lang Wang, Yan Zhang,[...]. Nat Commun 2014
52
5
26

Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease.
Guang-Nian Zhao, Ding-Sheng Jiang, Hongliang Li. Biochim Biophys Acta 2015
130
5
26

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
2054
5
26

Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Amedeo Lonardo, Fabio Nascimbeni, Alessandro Mantovani, Giovanni Targher. J Hepatol 2018
327
5
26

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy.
Ke-Qiong Deng, Aibing Wang, Yan-Xiao Ji, Xiao-Jing Zhang, Jing Fang, Yan Zhang, Peng Zhang, Xi Jiang, Lu Gao, Xue-Yong Zhu,[...]. Nat Commun 2016
54
5
26

Triggering and resolution of inflammation in NASH.
Susanne Schuster, Daniel Cabrera, Marco Arrese, Ariel E Feldstein. Nat Rev Gastroenterol Hepatol 2018
335
5
26

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Scott L Friedman, Vlad Ratziu, Stephen A Harrison, Manal F Abdelmalek, Guruprasad P Aithal, Juan Caballeria, Sven Francque, Geoffrey Farrell, Kris V Kowdley, Antonio Craxi,[...]. Hepatology 2018
400
5
26

Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges.
Yaxing Zhang, Xiao-Jing Zhang, Hongliang Li. Curr Drug Targets 2017
13
5
38

Time to step-up the fight against NAFLD.
Xiao-Jing Zhang, Zhi-Gang She, Hongliang Li. Hepatology 2018
24
5
26

Insights into innate immune signalling in controlling cardiac remodelling.
Yaxing Zhang, Zan Huang, Hongliang Li. Cardiovasc Res 2017
30
5
26

Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
Li-Hua Zhu, Aibing Wang, Pengcheng Luo, Xinan Wang, Ding-Sheng Jiang, Wei Deng, Xiaofei Zhang, Tao Wang, Yi Liu, Lu Gao,[...]. J Hepatol 2014
41
5
26

Innate immune regulatory networks in hepatic lipid metabolism.
Lan Bai, Hongliang Li. J Mol Med (Berl) 2019
34
5
26

IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling.
Ding-Sheng Jiang, Xiang Wei, Xiao-Fei Zhang, Yu Liu, Yan Zhang, Ke Chen, Lu Gao, Heng Zhou, Xue-Hai Zhu, Peter P Liu,[...]. Nat Commun 2014
111
4
21

Disruption of tumor necrosis factor receptor associated factor 5 exacerbates pressure overload cardiac hypertrophy and fibrosis.
Zhouyan Bian, Jia Dai, Nakano Hiroyasu, Hongjing Guan, Yuan Yuan, Lihua Gan, Heng Zhou, Jing Zong, Yan Zhang, Fangfang Li,[...]. J Cell Biochem 2014
23
4
21

Pharmacotherapy for NASH: Current and emerging.
Monica A Konerman, Jacob C Jones, Stephen A Harrison. J Hepatol 2018
173
4
21

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
4864
4
21

TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.
Sayaka Inokuchi-Shimizu, Eek Joong Park, Yoon Seok Roh, Ling Yang, Bi Zhang, Jingyi Song, Shuang Liang, Michael Pimienta, Koji Taniguchi, Xuefeng Wu,[...]. J Clin Invest 2014
116
4
21

Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1.
Juan-Juan Qin, Wenzhe Mao, Xiaozhan Wang, Peng Sun, Daqing Cheng, Song Tian, Xue-Yong Zhu, Ling Yang, Zan Huang, Hongliang Li. J Hepatol 2018
36
4
21

Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9.
Irma Garcia-Martinez, Nicola Santoro, Yonglin Chen, Rafaz Hoque, Xinshou Ouyang, Sonia Caprio, Mark J Shlomchik, Robert Lee Coffman, Albert Candia, Wajahat Zafar Mehal. J Clin Invest 2016
279
4
21

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
4410
4
21

Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice.
Hui Liu, Wen-Lin Cheng, Xi Jiang, Pi-Xiao Wang, Chun Fang, Xue-Yong Zhu, Zan Huang, Zhi-Gang She, Hongliang Li. Hypertension 2017
20
4
21


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.

Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy